ClinicalTrials.gg
Active, not recruitingNCT03301506Updated May 4, 2026

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

A Phase 3 interventional study of Seladelpar 5 mg Capsule and Seladelpar 10 mg Capsule in Primary Biliary Cirrhosis, sponsored by Gilead Sciences. Active, not recruiting at 109 sites in 25 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
340
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Read the detailed description

Primary:

To evaluate the long-term safety and tolerability of seladelpar

Secondary:

  • To evaluate the long-term efficacy of seladelpar
  • To evaluate the effect of seladelpar on patient-reported outcomes (pruritus)
02

Conditions studied

  • Primary Biliary Cirrhosis

Keywords

  • PBC
  • Primary Biliary Cholangitis (PBC)
03

In context

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

This study's planned enrollment of 340 is above the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.

Browse Liver Cirrhosis, Biliary studies →

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written (signed and dated)
  2. Participated in a PBC study with seladelpar
  3. Females of must use at least one barrier and a second effective birth control method during the study and for at least 90 days after the last dose. Male individuals who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose

Exclusion criteria

Exclusion Criteria:

Exclusion criteria are only applicable for individuals with a seladelpar interruption greater than 4 weeks prior to Day 1 of this study and for individuals who participated in CB8025-21838 irrespective of seladelpar interruption.

  1. Treatment-related adverse event (AE) leading to study drug discontinuation in a previous PBC study with seladelpar
  2. A medical condition, other than PBC, that in the Investigator's opinion would preclude full participation in the study or confound its results (eg, cancer, any active infection)
  3. or ALT above 3 × the (ULN)
  4. Total above 2 × ULN
  5. MELD score ≥ 12. For individuals on anticoagulation medication, evaluation of the baseline , in concert with any current dose adjustments in anti-coagulant medications, will be taken into account when calculating this score. This will be done in consultation with the medical monitor.
  6. Evidence of advanced PBC as defined by the Rotterdam criteria: albumin below 1× the lower limit of normal (LLN) AND total bilirubin above 1 × ULN)
  7. ≤45 mL/min/1.73 m2 (calculated by MDRD formula)
  8. Auto-immune hepatitis
  9. Primary sclerosing cholangitis
  10. Known history of alpha-1-antitrypsin deficiency
  11. Known history of chronic viral hepatitis
  12. For females, pregnancy or breast-feeding
  13. Use of colchicine, methotrexate, azathioprine, or long-term use of systemic (eg prednisone, prednisolone, budesonide) (>2 weeks) within 2 months prior to Screening
  14. Current use of fibrates or use of fibrates within 3 months prior to Screening
  15. Current use of obeticholic acid or use of obeticholic acid within 3 months prior to Screening
  16. Use of an experimental or unapproved treatment for PBC within 3 months prior to Screening
  17. History of diagnosed or treated, actively or within 2 years, or active evaluation for malignancy; localized treatment of squamous or non-invasive basal cell skin cancers and cervical carcinoma in-situ is allowed if appropriately treated prior to Screening
  18. Treatment with any other therapy or medical device within 30 days or within 5 half-lives, whatever is longer, prior to Screening
  19. Any other condition(s) that would compromise the safety of the individual or compromise the quality of the clinical study, as judged by the Investigator
  20. therapies (eg, cyclosporine, tacrolimus, anti-TNF or other immunosuppressive biologics)
  21. Other medications that effect liver or GI functions such as absorption of medications or the roux-en-y gastric bypass procedure may be prohibited and should be discussed with the medical monitor on a case-by-case basis
  22. Positive for:

    1. , defined as the presence of hepatitis B surface antigen
    2. , defined as the presence of hepatitis C virus ribonucleic acid (RNA)
    3. (HIV) antibody
  23. Active COVID-19 infection during screening

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
340 participants (estimated)

Study arms

  • Experimental
    Seladelpar 5 mg Capsules

    Drug: Seladelpar 5 mg Capsule

  • Experimental
    Seladelpar 10 mg Capsule

    Drug: Seladelpar 10 mg Capsule

Interventions

  • Participants will be assigned to a treatment group if tolerability issues noted in the previous study.

    Also known as: MBX-8025, Livdelzi®

  • Participants will be assigned to a treatment group unless there are tolerability issues.

    Also known as: MBX-8025, Livdelzi®

06

What researchers measure

Primary outcomes

  1. Treatment emergent adverse events (TEAEs) (National Cancer Institute {NCI} Common Terminology Criteria for Adverse Events {CTCAE} Version 5.0), biochemistry and hematology results

    Time frame: Through study completion, up to 60 Months

Secondary outcomes

  1. Death

    Occurrence of overall death

    Time frame: 60 Months

  2. Liver transplantation

    Occurrence of overall liver transplantation

    Time frame: 60 Months

  3. Change in MELD

    MELD score ≥ 15 for at least 2 consecutive visits

    Time frame: 60 Months

  4. Ascites

    Occurrence of overall ascites requiring treatment

    Time frame: 60 Months

  5. Hospitalization for variceal bleeding

    Hospitalization for new onset, or recurrence, of variceal bleeding

    Time frame: 60 Months

  6. Hospitalization for hepatic encephalopathy

    Hospitalization for new onset, or recurrence, hepatic encephalopathy (as defined by a West Haven score ≥ 2)

    Time frame: 60 Months

  7. Hospitalization for spontaneous bacterial peritonitis

    Hospitalization for new onset, or recurrence, spontaneous bacterial peritonitis (confirmed by culture from diagnostic paracentesis)

    Time frame: 60 Months

  8. Response on composite endpoint

    Alkaline phosphate (ALP)

    Time frame: 60 Months

  9. Response on composite endpoint

    Total bilirubin

    Time frame: 60 Months

  10. Normalization of ALP

    Proportion of subjects with normalization of ALP

    Time frame: 60 Months

  11. Laboratory Value: Serum Alkaline Phosphatase (ALP)

    Serum Alkaline Phosphatase (ALP)

    Time frame: Through study completion, up to 60 Months

  12. Laboratory Value: Aspartate Aminotransferase (AST)

    Aspartate Aminotransferase (AST)

    Time frame: Through study completion, up to 60 Months

  13. Laboratory Value: Alanine Aminotransferase (ALT)

    Alanine Aminotransferase (ALT)

    Time frame: Through study completion, up to 60 Months

  14. Laboratory Value: Gamma-glutamyl Transferase (GGT)

    Gamma-glutamyl Transferase (GGT)

    Time frame: Through study completion, up to 60 Months

  15. Laboratory Value: Bilirubin - Total Bilirubin

    Bilirubin - Total Bilirubin

    Time frame: Through study completion, up to 60 Months

  16. Laboratory Value: Bilirubin - Conjugated Bilirubin

    Bilirubin - Conjugated Bilirubin

    Time frame: Through study completion, up to 60 Months

  17. Laboratory Value: Bilirubin - Unconjugated Bilirubin

    Bilirubin - Unconjugated Bilirubin

    Time frame: Through study completion, up to 60 Months

07

Study locations

109 sites

Showing the first 100 of 109 sites across 25 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Levy C, Trivedi PJ, Kowdley KV, Gordon SC, Bowlus CL, Londono MC, Hirschfield GM, Gulamhusein A, Lawitz EJ, Vierling JM, Mayo MJ, Jacobson IM, Kremer AE, Corpechot C, Jones D, Buggisch P, Zhuo S, Proehl S, Heusner C, McWherter CA, Crittenden DB; ASSURE Investigators. Long-Term Efficacy and Safety of Selective PPARdelta Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results. Am J Gastroenterol. 2025 Jun 24;121(5):1140-53. doi: 10.14309/ajg.0000000000003603. Online ahead of print. PubMed 40553148 ↗
  • Mayo MJ, Vierling JM, Bowlus CL, Levy C, Hirschfield GM, Neff GW, Galambos MR, Gordon SC, Borg BB, Harrison SA, Thuluvath PJ, Goel A, Shiffman ML, Swain MG, Jones DEJ, Trivedi P, Kremer AE, Aspinall RJ, Sheridan DA, Dorffel Y, Yang K, Choi YJ, McWherter CA. Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2024 Jan;59(2):186-200. doi: 10.1111/apt.17755. Epub 2023 Oct 30. PubMed 37904314 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2017 (actual). Primary completion is estimated for Nov 2028, 131 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2017
First posted
Oct 4, 2017
StartActual
Dec 12, 2017
Primary completionEst.
Nov 2028
CompletionEst.
Dec 2028
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03301506
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 4, 2017
Start date
Dec 12, 2017
Primary completion
Nov 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 4, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seladelpar

Start the discussion